Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1962 1
1979 3
1980 3
1981 6
1982 7
1983 9
1984 8
1985 8
1986 9
1987 10
1988 12
1989 16
1990 13
1991 10
1992 7
1993 5
1994 5
1995 10
1996 10
1997 9
1998 5
1999 9
2000 6
2001 6
2002 14
2003 35
2004 34
2005 53
2006 58
2007 57
2008 59
2009 74
2010 58
2011 85
2012 69
2013 75
2014 82
2015 83
2016 70
2017 100
2018 86
2019 104
2020 121
2021 112
2022 138
2023 139
2024 59

Text availability

Article attribute

Article type

Publication date

Search Results

1,755 results

Results by year

Filters applied: . Clear all
Page 1
Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway.
Dang R, Wang M, Li X, Wang H, Liu L, Wu Q, Zhao J, Ji P, Zhong L, Licinio J, Xie P. Dang R, et al. J Neuroinflammation. 2022 Feb 7;19(1):41. doi: 10.1186/s12974-022-02400-6. J Neuroinflammation. 2022. PMID: 35130906 Free PMC article.
BACKGROUND: The inflammation and oxidative stress (OS) have been considered crucial components of the pathogenesis of depression. Edaravone (EDA), a free radical scavenger, processes strong biological activities including antioxidant, anti-inflammatory and neuroprotective …
BACKGROUND: The inflammation and oxidative stress (OS) have been considered crucial components of the pathogenesis of depression. Edaravo …
Amyotrophic Lateral Sclerosis: An Update for 2018.
Oskarsson B, Gendron TF, Staff NP. Oskarsson B, et al. Mayo Clin Proc. 2018 Nov;93(11):1617-1628. doi: 10.1016/j.mayocp.2018.04.007. Epub 2018 Jul 4. Mayo Clin Proc. 2018. PMID: 30401437 Review.
Two medications with modest benefits have Food and Drug Administration approval for the treatment of ALS: riluzole, a glutamate receptor antagonist, and, new in 2017, edaravone, a free radical scavenger. Many other encouraging treatment strategies are being explored in cli …
Two medications with modest benefits have Food and Drug Administration approval for the treatment of ALS: riluzole, a glutamate receptor ant …
Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities.
Soares P, Silva C, Chavarria D, Silva FSG, Oliveira PJ, Borges F. Soares P, et al. Ageing Res Rev. 2023 Jan;83:101790. doi: 10.1016/j.arr.2022.101790. Epub 2022 Nov 17. Ageing Res Rev. 2023. PMID: 36402404 Review.
Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of upper and lower motor neurons (MNs) leading to paralysis and, ultimately, death by respiratory failure 3-5 years after diagnosis. Edaravone and Riluzole, the only drugs currently approved for ALS t …
Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of upper and lower motor neurons (MNs) leading to paralysis and, ul …
Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
Witzel S, Maier A, Steinbach R, Grosskreutz J, Koch JC, Sarikidi A, Petri S, Günther R, Wolf J, Hermann A, Prudlo J, Cordts I, Lingor P, Löscher WN, Kohl Z, Hagenacker T, Ruckes C, Koch B, Spittel S, Günther K, Michels S, Dorst J, Meyer T, Ludolph AC; German Motor Neuron Disease Network (MND-NET). Witzel S, et al. JAMA Neurol. 2022 Feb 1;79(2):121-130. doi: 10.1001/jamaneurol.2021.4893. JAMA Neurol. 2022. PMID: 35006266 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the long-term safety and effectiveness of intravenous edaravone therapy for patients with ALS in a real-world clinical setting. ...Intravenous edaravone may not provide a clinically relevant additional benefit compared with standard therapy al …
OBJECTIVE: To evaluate the long-term safety and effectiveness of intravenous edaravone therapy for patients with ALS in a real-world …
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
Jaiswal MK. Jaiswal MK. Med Res Rev. 2019 Mar;39(2):733-748. doi: 10.1002/med.21528. Epub 2018 Aug 12. Med Res Rev. 2019. PMID: 30101496 Review.
Riluzole, a glutamatergic neurotransmission inhibitor, is the only drug approved by the USA Food and Drug Administration for ALS treatment with modest benefits on survival. Recently, an antioxidant drug, edaravone, developed by Mitsubishi Tanabe Pharma was found to be effe …
Riluzole, a glutamatergic neurotransmission inhibitor, is the only drug approved by the USA Food and Drug Administration for ALS treatment w …
An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.
Sun Y, Li X, Bedlack R. Sun Y, et al. Expert Rev Neurother. 2023 Jan;23(1):1-7. doi: 10.1080/14737175.2023.2174018. Epub 2023 Feb 1. Expert Rev Neurother. 2023. PMID: 36705941 Review.
Despite the overwhelming need for effective therapeutics for ALS, riluzole and edaravone were the only two FDA-approved disease-modifying therapies prior to 2022. ...
Despite the overwhelming need for effective therapeutics for ALS, riluzole and edaravone were the only two FDA-approved disease-modif …
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.
Johnson SA, Fang T, De Marchi F, Neel D, Van Weehaeghe D, Berry JD, Paganoni S. Johnson SA, et al. Drugs. 2022 Sep;82(13):1367-1388. doi: 10.1007/s40265-022-01769-1. Epub 2022 Sep 19. Drugs. 2022. PMID: 36121612 Review.
Riluzole, a neuroprotective agent offering only a modest survival benefit, has long been the sole disease-modifying therapy for ALS. Edaravone, which demonstrated statistically significant slowing of ALS disease progression, is gaining approval in an increasing number of c …
Riluzole, a neuroprotective agent offering only a modest survival benefit, has long been the sole disease-modifying therapy for ALS. Edar …
Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial.
Xu J, Wang A, Meng X, Yalkun G, Xu A, Gao Z, Chen H, Ji Y, Xu J, Geng D, Zhu R, Liu B, Dong A, Mu H, Lu Z, Li S, Zheng H, Chen X, Wang Y, Zhao X, Wang Y; TASTE Trial Investigators†. Xu J, et al. Stroke. 2021 Mar;52(3):772-780. doi: 10.1161/STROKEAHA.120.031197. Epub 2021 Feb 16. Stroke. 2021. PMID: 33588596 Clinical Trial.
The present clinical trial aimed at testing the effects of edaravone dexborneol versus edaravone on 90-day functional outcome in patients with acute ischemic stroke (AIS). ...RESULTS: One thousand one hundred sixty-five AIS patients were randomly allocated to the …
The present clinical trial aimed at testing the effects of edaravone dexborneol versus edaravone on 90-day functional outcome …
Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis.
Sever B, Ciftci H, DeMirci H, Sever H, Ocak F, Yulug B, Tateishi H, Tateishi T, Otsuka M, Fujita M, Başak AN. Sever B, et al. Int J Mol Sci. 2022 Feb 22;23(5):2400. doi: 10.3390/ijms23052400. Int J Mol Sci. 2022. PMID: 35269543 Free PMC article. Review.
This complexity is a major obstacle in defeating ALS. At present, riluzole and edaravone are the only drugs that have passed clinical trials for the treatment of ALS, notwithstanding that they showed modest benefits in a limited population of ALS. ...
This complexity is a major obstacle in defeating ALS. At present, riluzole and edaravone are the only drugs that have passed clinical …
Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke.
Hu R, Liang J, Ding L, Zhang W, Liu X, Song B, Xu Y. Hu R, et al. Int Immunopharmacol. 2022 Dec;113(Pt A):109315. doi: 10.1016/j.intimp.2022.109315. Epub 2022 Oct 21. Int Immunopharmacol. 2022. PMID: 36279668
Edaravone dexborneol (EDB) is a traditional prescription that consists of two components, edaravone and (+)-borneol, which have synergistic antioxidant and anti-inflammatory activities in animal models of ischemic stroke. ...
Edaravone dexborneol (EDB) is a traditional prescription that consists of two components, edaravone and (+)-borneol, which hav …
1,755 results